UBS Group’s TFF Pharmaceuticals, Inc. Common Stock TFFP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-675
| Closed | -$1.36K | – | 10648 |
|
|
2024
Q3 | $1.36K | Sell |
675
-60
| -8% | -$118 | ﹤0.01% | 8656 |
|
|
2024
Q2 | $1.22K | Sell |
735
-392
| -35% | -$1.03K | ﹤0.01% | 8626 |
|
|
2024
Q1 | $6.81K | Sell |
1,127
-686
| -38% | -$4.49K | ﹤0.01% | 7433 |
|
|
2023
Q4 | $12.7K | Sell |
1,813
-1,856
| -51% | -$14.4K | ﹤0.01% | 7339 |
|
|
2023
Q3 | $32.1K | Sell |
3,669
-1,475
| -29% | -$13.8K | ﹤0.01% | 6563 |
|
|
2023
Q2 | $60.4K | Sell |
5,144
-47
| -0.9% | -$676 | ﹤0.01% | 6365 |
|
|
2023
Q1 | $88.9K | Buy |
5,191
+628
| +14% | +$13.6K | ﹤0.01% | 5990 |
|
|
2022
Q4 | $120K | Buy |
4,563
+659
| +17% | +$31.3K | ﹤0.01% | 5940 |
|
|
2022
Q3 | $396K | Buy |
3,904
+217
| +6% | +$29.4K | ﹤0.01% | 4542 |
|
|
2022
Q2 | $521K | Buy |
3,687
+405
| +12% | +$56.5K | ﹤0.01% | 4236 |
|
|
2022
Q1 | $518K | Sell |
3,282
-196
| -6% | -$31.7K | ﹤0.01% | 4662 |
|
|
2021
Q4 | $771K | Buy |
3,478
+286
| +9% | +$55.3K | ﹤0.01% | 4618 |
|
|
2021
Q3 | $616K | Buy |
3,192
+2,987
| +1,457% | +$634K | ﹤0.01% | 4579 |
|
|
2021
Q2 | $49K | Sell |
205
-32
| -14% | -$8.78K | ﹤0.01% | 6451 |
|
|
2021
Q1 | $81K | Sell |
237
-370
| -61% | -$150K | ﹤0.01% | 6126 |
|
|
2020
Q4 | $217K | Buy |
607
+560
| +1,191% | +$216K | ﹤0.01% | 5195 |
|
|
2020
Q3 | $22K | Sell |
47
-88
| -65% | -$24.8K | ﹤0.01% | 6252 |
|
|
2020
Q2 | $19K | Buy |
135
+59
| +78% | +$7.46K | ﹤0.01% | 6601 |
|
|
2020
Q1 | $7K | Buy |
76
+56
| +280% | +$6.66K | ﹤0.01% | 7172 |
|
|
2019
Q4 | $3K | Buy |
+20
| New | +$2.57K | ﹤0.01% | 7772 |
|
Other funds holding TFFP
UBS Group's TFFP Position: Q4 2024 in Review
UBS Group sold out of TFF Pharmaceuticals, Inc. Common Stock (TFFP) in Q4 2024, closing a stake of 675 shares — an estimated $1.36K sold.
UBS Group first reported a position in TFFP in Q4 2019 and held it in 20 quarters. The position peaked at $771K in Q4 2021. 4 funds tracked by Wall St. Rank hold TFFP as of Q4 2024.
- UBS Group reported no remaining TFF Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- UBS Group sold 675 TFF Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $1.36K.
- UBS Group first reported a position in TFF Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 20 quarters.
- UBS Group's TFF Pharmaceuticals, Inc. Common Stock position peaked at $771K in Q4 2021.
- 4 funds tracked by Wall St. Rank held TFF Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.